Smith, Moore & Co. Amgen Inc Transaction History

Smith, Moore & Co.

$1.03 Billion
Q3 2024

A detailed history of Smith, Moore & Co. transactions in Amgen Inc stock. As of the latest transaction made, Smith, Moore & Co. holds 7,583 shares of AMGN stock, worth $2.01 Million. This represents 0.24% of its overall portfolio holdings.

Number of Shares

7,583

Previous 6,996 8.39%

Holding current value

$2.01 Million

Previous $2.19 Million 11.81%

% of portfolio

0.24%

Previous 0.23%

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 12, 2024	BUY	$309.38 - $337.38 $181,606 - $198,042	587 Added 8.39%	7,583 $2.44 Million
Q2 2024 Aug 14, 2024	BUY	$262.75 - $319.31 $534,696 - $649,795	2,035 Added 41.02%	6,996 $2.19 Million
Q1 2024 May 10, 2024	BUY	$268.87 - $324.56 $29,306 - $35,377	109 Added 2.25%	4,961 $1.41 Million
Q4 2023 Feb 13, 2024	SELL	$255.7 - $288.46 $10,228 - $11,538	-40 Reduced 0.82%	4,852 $1.4 Million
Q3 2023 Nov 14, 2023	SELL	$218.65 - $271.46 $115,884 - $143,873	-530 Reduced 9.77%	4,892 $1.31 Million
Q2 2023 Aug 11, 2023	BUY	$214.27 - $253.37 $50,996 - $60,302	238 Added 4.59%	5,422 $1.2 Million
Q1 2023 May 12, 2023	SELL	$225.79 - $275.2 $14,676 - $17,888	-65 Reduced 1.24%	5,184 $1.25 Million
Q4 2022 Feb 13, 2023	SELL	$229.03 - $291.01 $195,591 - $248,522	-854 Reduced 13.99%	5,249 $1.38 Million
Q3 2022 Nov 14, 2022	SELL	$224.46 - $253.15 $49,830 - $56,199	-222 Reduced 3.51%	6,103 $1.38 Million
Q2 2022 Aug 12, 2022	BUY	$230.71 - $256.74 $23,071 - $25,674	100 Added 1.61%	6,325 $1.54 Million
Q1 2022 May 12, 2022	SELL	$219.27 - $242.57 $19,515 - $21,588	-89 Reduced 1.41%	6,225 $1.51 Million
Q4 2021 Feb 08, 2022	BUY	$198.88 - $227.6 $82,137 - $93,998	413 Added 7.0%	6,314 $1.42 Million
Q3 2021 Nov 12, 2021	BUY	$212.27 - $248.7 $27,595 - $32,331	130 Added 2.25%	5,901 $1.26 Million
Q2 2021 Aug 10, 2021	BUY	$233.58 - $259.14 $21,022 - $23,322	90 Added 1.58%	5,771 $1.41 Million
Q1 2021 May 14, 2021	BUY	$221.91 - $258.6 $776,685 - $905,100	3,500 Added 160.48%	5,681 $1.41 Million
Q4 2020 Feb 16, 2021	BUY	$216.38 - $257.67 $15,362 - $18,294	71 Added 3.36%	2,181 $501,000
Q3 2020 Nov 12, 2020	SELL	$234.65 - $260.95 $109,816 - $122,124	-468 Reduced 18.15%	2,110 $536,000
Q2 2020 Aug 10, 2020	BUY	$197.81 - $242.74 $41,342 - $50,732	209 Added 8.82%	2,578 $608,000
Q1 2020 May 15, 2020	SELL	$182.24 - $241.7 $5,831 - $7,734	-32 Reduced 1.33%	2,369 $480,000
Q4 2019 Feb 07, 2020	SELL	$189.21 - $243.2 $9,649 - $12,403	-51 Reduced 2.08%	2,401 $579,000
Q3 2019 Nov 07, 2019	BUY	$174.11 - $208.62 $98,023 - $117,453	563 Added 29.8%	2,452 $474,000
Q2 2019 Aug 15, 2019	BUY	$166.7 - $195.41 $85,517 - $100,245	513 Added 37.28%	1,889 $348,000
Q1 2019 May 07, 2019	SELL	$180.87 - $203.88 $90,254 - $101,736	-499 Reduced 26.61%	1,376 $261,000
Q4 2018 Feb 15, 2019	BUY	$178.4 - $208.25 $79,744 - $93,087	447 Added 31.3%	1,875 $365,000
Q3 2018 Nov 15, 2018	BUY	$185.29 - $208.89 $9,820 - $11,071	53 Added 3.85%	1,428 $296,000
Q2 2018 Aug 14, 2018	BUY	$166.05 - $186.51 $228,318 - $256,451	1,375 New	1,375 $254,000
Q1 2018 May 14, 2018	SELL	$169.43 - $198.0 $397,482 - $464,508	-2,346 Closed	0 $0
Q4 2017 Feb 09, 2018	BUY	$168.79 - $188.59 $337 - $377	2 Added 0.09%	2,346 $408,000
Q3 2017 Nov 02, 2017	BUY	$167.29 - $191.0 $392,127 - $447,704	2,344	2,344 $437,000

Others Institutions Holding AMGN

# of Institutions

3,125

Shares Held

409M

Call Options Held

7.56M

Put Options Held

7.2M

View Full List

About AMGEN INC

Ticker AMGN
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 534,931,008
Market Cap $141B
Description
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces th...

More about AMGN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Smith, Moore & Co., based on Form 13F filings with the SEC.

News

Stay updated on Smith, Moore & Co. with notifications on news.

Account